PAP
ZVRA icon

Persistent Asset Partners’s Zevra Therapeutics ZVRA Stock Holding History

Persistent Asset Partners’s Portfolio ZVRA Stock Details ZVRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$122K Buy
+8,499
New +$94.5K 0.04% 264
2025
Q1 		– Sell
-12,831
Closed -$101K – 217
2024
Q4 		$101K Buy
+12,831
New +$110K 0.08% 102

Other funds holding ZVRA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Persistent Asset Partners's ZVRA Position: Q2 2026 in Review

Persistent Asset Partners opened a new position in Zevra Therapeutics (ZVRA) in Q2 2026: 8,499 shares worth $122K. The stake represents 0.04% of the portfolio and ranks #264 among its holdings. This is a return to the name: Persistent Asset Partners previously reported a position in ZVRA as recently as Q4 2024.

Persistent Asset Partners first reported a position in ZVRA in Q4 2024 and has held it in 2 quarters since. 158 funds tracked by Wall St. Rank hold ZVRA as of Q2 2026.

  • Persistent Asset Partners held 8,499 shares of Zevra Therapeutics worth $122K as of Q2 2026.
  • Zevra Therapeutics was a new Persistent Asset Partners position in Q2 2026.
  • Zevra Therapeutics made up 0.04% of Persistent Asset Partners's portfolio in Q2 2026, its #264 holding.
  • Persistent Asset Partners first reported a position in Zevra Therapeutics in Q4 2024 and has held it in 2 quarters since.
  • 158 funds tracked by Wall St. Rank held Zevra Therapeutics as of Q2 2026.

Based on Persistent Asset Partners's 13F filing for Q2 2026, filed 7 Aug 2026.